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Background: Standard treatments against bacterial infections are becoming ineffective 
due to the rise of antibacterial resistance worldwide. Classical approaches to develop 
new antibacterial agents are not sufficient to fulfil the current pipeline, therefore new 
strategies are currently being conducted devised in the field of antibacterial discovery.   
Objectives: The objective of this narrative review is to compile the most successful 
strategies in which research on drug discovery within the antibacterial context is 
currently ongoing. 
Sources: Peer-reviewed publications from the MEDLINE database with robust data 
addressing the discovery of new antibacterial agents in the current pipeline have been 
selected. 
Content: Several strategies to discovery new antibacterial are described in this review, 
such as: i. Derivatives of known antibacterial agents. The activity of a known 
antimicrobial agent can be improved through two strategies: a) Modification of the 
original chemical structure of an antimicrobial agent which circumvents antibacterial 
resistant mechanisms, and b) Development of a compound that inhibits the 
mechanisms of resistance to an antibacterial agent; ii. New antibacterial agents 
targeting new proteins; iii. Inhibitors of virulence factors; iv. Nanoparticles; v. 
Antimicrobial peptides (AMPs) and peptidomimetics; vi. Phage therapy and 
enzybiotics, and vii. Antisense oligonucleotides. 
Implications: This review intends to provide a positive message affirming that several 
different strategies to design new antibacterial agents are currently being developed, 
and we are therefore confident that in the near future some of the most promising 
approaches will come to fruition. 
Introduction 
The development of new therapeutic strategies seems to have reached a dead end. 
Despite the urgent need to find new antibacterial products, many pharmaceutical 
companies, including a significant number of large companies, have abandoned new 
antibiotic research programs, investing their R&D resources in other therapeutic areas 
[1]. Besides private efforts, research groups at the hospital or academic level outside 
the industry may play an important role in discovering new antibiotics. This narrative 
review describes the major strategies implemented to design and develop new 
antibacterial agents. 
Improving known antibacterial agents 
The activity of a known antimicrobial agent can be improved through two strategies: i) 
Modification of the basic chemical structure of an antimicrobial agent, such as 
tigecycline, which circumvents antibacterial resistance mechanisms. It is a derivative of 
minocycline with a 9-tert-butyl-glycylamido side chain added to the D ring at the ninth 
position of the molecule, which avoids the effect of specific tetracycline efflux pumps 
or ribosomal protection, two of the mechanisms of tetracycline resistance [2]. 
Cefiderocol can also be considered a cephalosporin-derivative since it has been linked 
to a siderophore which helps to reach the periplasmic space and has enhanced 
stability to β-lactamases. It shows good activity against Enterobacteriaceae and non-
fermenters such as Pseudomonas aeruginosa and Acinetobacter baumannii, and it is 
currently in Phase III studies (Table 1).  ii) Compounds inhibiting the mechanisms of 
resistance to an antibacterial agent. In this regard, several approaches such as new β-
lactamases inhibitors (BLIs) are being used [3]. Two main groups of BLIs are being 
developed: firstly, the diazabicyclooctane group (i.e., avibactam or relebactam) which 
does not show inhibition of metallo-β-lactamases (MBLs); however, the combination 
with aztreonam  cover also MBL-producing Enterobacteriaceae, since aztreonam has 
activity against the bacteria producing MBLs; secondly, the boronate BLI group. The 
main example of this group is vaborbactam, which also does not show inhibition of 
MBLs and is combined with meropenem. Inhibitors of efflux pumps allowing the 
antibiotic to accumulate in the bacterial cell are being developed. Some examples 
include phenylalanine-arginine-b-naphthylamide (PAβN) or the most recent indole-2-
carboxamides. Nevertheless, none of these inhibitors have reached the clinical trial 
stage, mainly due to toxicity. Another area of research is the development of inhibitors 
of RecA, which plays an important role in SOS response and has been shown to 
potentiate antibiotic activity and block the evolution of antibiotic resistance [4,5]. 
New antibacterial agents targeting new proteins 
Although 30 antibacterial agents are currently in the pipeline [6] few are actually 
considered new (Table 1). It was thought that the advent of bacterial genomics would 
open the door to the discovery of new antibiotics. However, while it is true in part that 
the search for essential targets using computational analysis is feasible, finding an in 
vitro inhibitor of these protein targets is difficult and faces development hurdles such 
as limitations in penetrating the bacteria. Therefore, there has been no success with 
this approach.  
However, the traditional pathway of identifying microorganisms from a rich ecological 
niche producing an antibiotic as a secondary metabolite, still has potential for the 
discovery of new antibiotics. Moreover, some authors are trying to find 
microorganisms producing antibiotics from recondite niches such as marine samples 
(invertebrates or algae), insects and invertebrate organisms (e.g., symbionts and 
plants) [7]. An alternative to this approach is searching for new antibacterial 
compounds from the metabolism of microorganisms present in human microbiota or 
from the microbiome of different sources; in this regard lugdunin, a macrocyclic 
thiazolidine peptide antibiotic produced by Staphylococcus lugdunensis, has shown to 
be active against a group of Gram-positive pathogens including Staphylococcus aureus 
[8]. However, the mode of action is unknown. Regarding the microbiome, there are 
two approaches: i. The capture of biosynthetic gene clusters from whole metagenomic 
DNA, and ii. The prediction of natural product structures from primary sequence data 
by means of bioinformatic tools and their production by chemical synthesis. These 
approaches have led to the discovery of two molecules: tetarimycin and humimycin. 
The former is a tetracyclic antibiotic active against methicillin-resistant S. aureus 
(MRSA) from soil microbiome and the latter inhibits lipid II flipase and shows activity 
against Gram-positive bacteria including S. aureus and Streptococcus pneumonia and 
interesting synergy with some β-lactam antibiotics [9,10]. 
Virulence blockers 
An alternative to the classical approach of drug development is to affect pathogenicity 
by targeting specific virulence factors involved in this process. This strategy aims to , 
prvent the bacterium to develop resistance and thus contain the spread. Molecules 
interfering with virulence factors will disarm the pathogen, thereby allowing bacterial 
clearance by the host immune system. There is a myriad of factors involved in bacterial 
virulence that are being investigated as targets for new agents including the following 
categories:  
1. Determinants involved in host cell attachment inhibiting access and translocation 
into the host tissue. Molecules targeting fimbria, such as the FimH antagonist 
mannosides , and the antibody  scFv-Fc KP3 targeting type 3 fimbrial subunit [11–13], 
have shown good in vivo effects in mice models (Table 2).  Pilicides, pili formation 
inhibitors and the glycosylated molecules mucins  are in discovery phases  [11,12,14].     
2. Actors involved in host immune modulation. Lipid A inhibitors include LpxC-1 [15], 
the substituted sulfone-based hydroxamates with good  in vitro efficacy [16] and 
ACHN-975, having failed Phase I [17] (Table 2). Another molecule, erianin, a Sortase A 
inhibitor which interferes in host immune recognition and attachment in host surfaces 
affects virulence in S. aureus murine infections [18]. 
3. Biofilm modulation (limiting adhesion, affecting the extracellular matrix and 
disturbing mature biofilm). A number of small molecule inhibitors have been identified 
and recently reviewed [19]. Agents of natural origin such as flavonolignans and 
streptorubin B [20], cyclosporine and its derivative valspodar, have shown to be good 
antibiofilm agents [14,21]. AR-105 entered the Phase II clinical phase as an adjunctive 
treatment [6,22,23] (Table 2). 
4. Global regulators of virulence. These include anethole and  SE-1, tested in vivo and 
in vitro, respectively [24,25] (Table 2). Inhibition of two-component systems have also 
shown to block the pathogenesis of clinically relevant bacteria [14] although only 
savirin and  LED209 have shown good in vivo results [26,27] (Table 2).    
 5. The quorum sensing (QS) network, which mediates bacterial communication and is 
key in the infection process. QS quenching includes the acyl-homoserine lactone 
lactonases effective against P. aeruginosa. The main advantage of this approach is that 
modulation of one QS system allows interference in other systems [28]. 
6. Toxins secreted by pathogenic bacteria required for bacteria-host interactions and 
evasion of the immune system. The anti α–toxin antibody S. aureus (MEDI4893) that 
completed the Phase II trial in 2018 (results not yet available)  is promising [29] (Table 
2). Another interesting case is the mAb targeting toxin B from Clostridiodes difficile 
(Bezlotoxumab) the first FDA-approved anti-virulence agent to be used in combination 
with current therapy to prevent recurrent C. difficile infections[30]. 
7. Bacterial functional membrane microdomain-associated proteins related to 
signalling networks. Small molecules interfering with the metabolic pathway of 
polyisoprenoid lipid biosynthesis have shown to attenuate bacterial virulence. 
Zaragozic acid alters oligomerization of the penicillin-binding protein PBP2a in MRSA 
reverting the resistant phenotype [28]. 
8. Type three secretion system, a major Gram-negative virulence factor which allows 
secretion of effector proteins involved in pathogenicity. Inhibitors of this system 
include licoflavonol in Salmonella Typhimurium [31] and salicylidene acylhydrazides 
active against infections of Chlamydia trachomatis [32] (Table 2). 
9. Liposomes interfering in the progression of infection. CLA02 has completed the 
Phase I  trial [33] and improved outcomes were shown as a combination therapy in  
mice [34] (Table 2). One of the advantages of anti-virulence agents is the preservation 
of the host’s microbiome as commensal bacteria often lack the features targeted by 
these agents. In terms of drug development, although to date no anti-virulence agent 
has entered clinical study phases, it is most likely that larger clinical trials will be 
needed to prove their therapeutic efficacy  as adjuvants (as may be the case for other 
agents under other approaches also discussed in this work) of current antibiotic 
treatments when effective treatments are available. Additionally, it is expected that 
the administration of a combination of several anti-virulence agents will be required 
and effectively attenuate the bacteria. Another hurdle lies in the fact that 
administration of the anti-virulence drug must be in concordance with the time at 
which the targeted factor is expressed. Finally, since one of the features of these 
molecules is that the effectiveness is dependent  on the immune host response, these 
therapies will not be adequate to treat immunocompromised patients. 
 
Nanoparticles 
Nanoparticles (NPs) are defined as particles or materials within the nanometer scale 
[35]. Although some metals like silver or copper have antibacterial activity in their bulk 
form, others only have it as NPs against bacteria. The mechanisms of action of these 
particles have not been completely described yet, but three processes are 
hypothesized to occur concomitantly: induction of oxidative stress, non-oxidative 
mechanisms and in a minor way, interaction of released metal ion with functional 
groups of proteins and nucleic acids [36,37]. 
Specific factors such as size, zeta potential (electrokinetic potential), charge, surface 
morphology and crystal structure determine metal NP antimicrobial activity [37]. NPs 
can both disrupt bacterial membranes and hinder the formation of biofilms. Smaller 
NPs provide greater biofilm inhibition (e.g., Ag, ZnO, Mg or NO NPs) and rod-shaped 
NPs are better at inhibiting biofilms than spherical NPs [38]. 
NP cytotoxicity is a drawback and must be carefully regarded. ZnO and Ag NPs have 
been described as cytotoxic at bacterial inhibitory concentrations. To overcome this 
issue, it has been proposed that NPs must be delivered locally at the infection site to 
confine the NPs and their harmful effects to eukaryotic cells [36].Antimicrobial 
peptides (AMPs) and peptidomimetics 
AMPs are ubiquitous immune effectors that aid the host in fighting pathogens. 
Although the classically proposed mechanism of action is membrane permeabilization, 
other mechanisms, including inhibition of protein, DNA and RNA synthesis and gene 
material degradation, also take place. Their activity is based on their composition and 
secondary structure[39].  
AMPs can be classified based on their secondary structure into α–helical AMPs (e.g., 
cathelicidins), β–sheet containing AMPs (e.g., α– or β–defensins), AMPs with a β–
hairpin or loop stabilized by a single disulphide bond or cyclisation of the peptide chain 
(e.g., thanatin) and short AMPs with extended conformations (e.g., indolicidin) [40]. 
 Due to their mechanism of action, it has been proposed that these molecules are 
synergistic in combination with antibiotics that have difficulty in penetrating bacterium 
or when the resistance mechanism to that antibiotic is related to membrane 
modification [41]. 
AMPs usually fail preclinical studies due to low stability or high in vivo toxicity. In the 
last decades few natural AMPs have been commercialized, none of which was a linear 
peptide [40]. Most of the AMPs that continue in clinical trials are for topical use. The 
following examples represent promising AMPs that have undergone clinical trials with 
different applications: OP-145 completed Phase II [40,42–44], two AMPs targeting C. 
difficile, surotomycin which was discontinued after two Phase III studies [45–47] and 
NVB-302, has completed Phase I [40,48–50]. 
Peptidomimetics are defined as sequences purposely designed to mimic a peptide or 
its function but no single α-amino acid makes up the backbone structure. These 
sequences usually have enhanced in vivo stability and lower toxicity than usual α-
helical AMPs [40]. 
Amongst the different peptidomimetics, ceragenins are resistant to proteases and are 
easy to produce on a large scale [51]. Two of the most active are: CSA-131 active 
against colistin-resistant A. baumannii, P. aeruginosa and Klebsiella pneumoniae 
strains and anaerobic bacteria [52–55] and CSA-13 with good  antibiofilm activity 
[56,57] (Table 4). 
Murepavadin, which belongs to a novel class of outer membrane protein [6] is of 
special interest, although it was recently halted in Phase III [41,58–60] (Table 4). 
While it has been suggested that there is little to no resistance to AMPs (and/or to 
peptidomimetics), cross-resistance can arise when experimentally exposing S. aureus 
against pexiganan [61]. 
Phage therapy and enzybiotics 
The use of lytic phages has been restricted to Eastern European countries, particularly 
Georgia and Poland where phage cocktails are commercially available (Table 4). 
Regarding Western European countries, a study called Phagoburn was conducted in 
Belgium, France, and Switzerland from 2013 to 2017 to evaluate phage therapy for 
treating burn wounds infected with E. coli and P. aeruginosa [62] (Table 4). 
Additionally, the ambitious Phage 4 cure project, is currently ongoing in Germany and 
includes the development of inhalable bacteriophages to treat P. aeruginosa infections 
from manufacturing to preclinical studies following international quality standards 
[63,64] (Table 4). 
Another antibacterial approach, the so-called enzybiotics, involves the use of phage-
derived enzymes to specifically attack different species or even bacterial serotypes. 
These lysins were first described in the 1960s and act by degrading peptidoglycan and 
inducing bacterial lysis by osmotic imbalance and have shown good antibacterial 
activity bacteria. Endolysins, in particular Cpl-711, have recently shown good results 
when administered in mice previously challenged with S. pneumoniae[65] (Table 4). 
Alternatively, polysaccharide depolymerases are also currently being studied as they 
degrade carbohydrates of bacterial membranes. Thus, the use of this family of 
enzymes in the disruption of biofilms and against encapsulated bacteria has generated 
enormous interest [63,65,66]. 
Although phage therapy is seen as a potentially promising alternative to fight against 
antimicrobial resistant pathogens, there are still several hurdles to overcome. One is 
pharmacokinetics, as high doses of phages are needed to eliminate bacterial 
population (even small communities) since they have to replicate inside the host cell to 
exert their bactericidal effect. In terms of host response, considerations regarding 
immune reaction, through neutralizing antibodies, derived from the action of 
bacteriophages must also be considered. Finally, the threat of the rise of bacterial 
resistance to bacteriophages should be taken into account and one strategy to 
overcome this issue lies in the combination of phages with classical antibiotics. 
Regarding enzybiotics, the main limitation is their weak stability and lack of solubility 
requiring the need for chemical engineering. 
Antisense oligonucleotides 
Oligonucleotides can be used to inhibit gene expression both in eukaryotes and 
prokaryotes. These molecules act on different levels in the gene expression regulation 
pathways. Depending on their mechanism these molecules are classified as 
transcription process inhibitors (e.g., Triplex Forming Oligonucleotides aimed against 
DNA), translation process inhibitors (e.g., antisense oligonucleotides, small interfering 
RNAs, ribozymes and microRNAs; aimed at mRNA) and oligonucleotides blocking 
protein activity (e.g., aptamers or decoy oligonucleotides for transcription factors). 
Antisense oligonucleotides are single stranded DNA mimicking oligos of around 20 
nucleotides that bind mRNA to modulate gene expression but do not affect nucleotide 
translation [67]. The most commonly investigated antisense oligonucleotides are: i) 
phosphorothioate oligodeoxynucleotides (S-oligos); ii) locked nucleic acids; iii) peptide 
nucleic acid (PNAs); iv) phosphorodiamidate morpholino-oligomers (PMOs) [68]. 
Antisense oligonucleotides can be used to fight antimicrobial resistance by inhibiting 
essential gene expression through RNA silencing. The main drawback of this strategy is 
achieving concentrations high enough inside the bacterium which has been addressed 
using Cell Penetrating Peptides (CPPs) that aid in the effective intracellular delivery of 
the oligomers.  
The potential of antisense oligonucleotides as antimicrobials has been shown by 
different research groups (e.g., CPP-PMO [69], CPP-PNA [70], PNA targeting polA [71] 
and PNA conjugates [72] (Table 3)). 
 
Conclusion 
Although as seen in this review there are currently several strategies being carried out 
for the discovery of new antibacterial agents, the time is not yet ripe for complacency. 
Therefore, more traditional and non-traditional approaches are needed to ensure a 
future with effective treatments against infectious diseases caused by multidrug 
resistant bacteria. To make this possible, more funding opportunities are needed for 
public research in the field (current programs such as Carb-X and ENABLE have 
demonstrated to be insufficient) and new incentives are necessary to induce the 
industry to return to the discovery of antibacterial agents. In this sense, a 
“subscription” style payment model such as the one that the United Kingdom recently 
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Table 2. Description of virulence blockers in the research pipeline 
Virulence 
categories
Agent Action Bacterial target Infectious disease targeted Current stage References
Pilicides (bicyclic 2-
pyridones)
Inhibition of pili 
formation/biogenesis and 
regulation





Host receptor analogues 
inhibiting FimH component of 
type I fimbriae
Uropathogenic Escherichia coli  (UPEC)  urinary tract infection casued by UPEC Preclinical a Klein_2010
ScFv-Fc KP3 (synthetic 
antibody)
Targeting type 3 fimbrial 
subunit in Klebsiella 
pneumoniae
Klebsiella pneumoniae K. pneumoniae  infections Preclinical b Wang_2016
Mucins
Interference with bacterial 
adhesins (mimic host cell 
receptor glycosylation)
Escherichia coli, Salmonella, Helicobacter 
pylori, Staphylococcus aureus and Bacillus 
subtilis




Inhibition of the lipid A 
biosynthetic enzyme LpxC
Acinetobacter baumannii A. baumannii  infection Preclinical c Lin_2012
ACHN-975
Inhibition of the lipid A 
biosynthetic enzyme LpxC
Klebsiella pneumoniae, Pseudomonas 
aeruginosa and Escherichia coli
K. pneumoniae, P. aeruginosa and E. coli 
infections
Phase I (interrupted) d Erwin_2016
Substituted sulfone-based 
hydroxamates
Inhibition of the lipid A 
biosynthetic enzyme LpxC
Klebsiella pneumoniae, Escherichia coli, 
Enterobacter aerogenes, and Citrobacter 
freundii
Infections caused by K. pneumoniae, E. 




Sortase A inhibitor (Sortase A 
anchors cell surface molecules 
involved in pathogenesis in 
Gram-positive bacteria)
Staphylococcus aureus S. aureus infections Preclinical Ouyang_2018
Hydnocarpin-type 
flavonolignans ( isolated 
from Silybum marianum) 
ref. Vimberg_2015)
Inhibition of the icaADBC-
dependent biofilm formation 
pathway
Staphylococcus aureus S. aureus -mediated biofilm infections Discovery Vimberg_2015
Streptorubin B (isolated 





S. aureus -mediated biofilm infections Discovery Suzuki_2015
Cyclosporine and valspodar 
(cyclosporine -derivative )
Inhibition of the Rgg2/Rgg3 
regulatory system 
Streptococcus pyogenes Streptococcus pyogenes  infections Discovery Aggarwal_2015
AR-105 (monoclonal 
antibody)
Blockage of the polysaccharide 
alginate (surface 
polysaccharide of P. 
aeruginosa involved in biofilm 
formation and adhesion
Pseudomonas aeruginosa
Ventilated-acquired pneumoniae caused 







Repression of the production 
of the cholera toxin and the 
toxin coregulated pilus
Vibrio cholerae V. cholerae  infections Preclinical f Zahid_2015
 SE-1 Inhibition of VirF expression Shigella flexneri Shigellosis Discovery  g Koppolu_2013
Savirin
Inhibition of the 
transcriptional regulator AgrA 
(affects the regulatory cascade 
including hla, psm alpha, pvl 
(lukS), agrA,and agrC.. )
Staphylococcus aureus





autophosphorylation of the 
sensor kinase QseC ( involved 
in the regulation of of 
virulence gene expression as 
motility via flhDC operon in 
Escherichia coli  or regulation 
of the pathogenicity island LEE 
in enterohemorrhagic 
Escherichia coli and involved in 
virulence in Salmonella 
Typhimurium   and  Francisella 
tularensis )
Escherichia coli, Salmonella Typhimurium 
and Francisella tularensis  
Infections caused by E. coli, Salmonella 
Typhimurium and Francisella tularensis  
Preclinical i
Mühlen_2016 / 







Targeting the acyl-homoserine 
lactones (quorum sense 
signals)
Pseudomonas aeruginosa and 
Acinetobacter baumannii 





Binding to α–toxin of S. 
aureus
Staphylococcus aureus
Diabetic food ulcers infected with S. 
aureus





Binding to toxin B from 
Clostridiodes difficile
Clostridiodes difficile
Prevention of recurrent C. difficile 
infections (in combination with current 
therapy)









zaragozic acid Sterol synthesis inhibitor 
Meticillin-resistant Staphylococcus 
aureus  (MRSA)
S. aureus  infections Preclinical Fleitas_2019
licoflavonol 
Regulation of transcription of 
sicA/invF  and transportation 
of SipC
Salmonella Typhimurium S.  Typhimurium infection Discovery Guo_2016
salicylidene acylhydrazides Targeting T3SS
Salmonella Typhimurium and Chlamydia 
trachomatis




Liposomes acting as a toxin 
trap
Staphylococcus aureus and Streptococcus 
pneumoniae
Severe community-acquired S. 
pneumoniae infection











a Mannosides have shown significantly decreased colonization levels in UPEC and the ST131 clinical multidrug resistant strain of 
E. coli murine infections (13: Klein T, Abgottspon D, Wittwer M, Rabbani S, Herold J, Jiang X, Kleeb S, Lüthi C, Scharenberg M, 
Bezençon J, Gubler E, Pang L, Smiesko M, Cutting B, Schwardt O, Ernst B. 2010. FimH Antagonists for the Oral Treatment of 
Urinary Tract Infections: From Design and Synthesis to in Vitro and in Vivo Evaluation. J Med Chem 53:8627–8641. 
b scFv-Fc KP3 has shown to inhibit biofilm formation and reduce bacterial burden in a mouse lung infection model (14: Wang Q, 
Chang C-S, Pennini M, Pelletier M, Rajan S, Zha J, Chen Y, Cvitkovic R, Sadowska A, Heidbrink Thompson J, Yu Lin H, Barnes A, 
Rickert K, Wilson S, Stover CK, Dall’Acqua WF, Chowdhury PS, Xiao X. 2016. Target-Agnostic Identification of Functional 
Monoclonal Antibodies Against Klebsiella pneumoniae Multimeric MrkA Fimbrial Subunit. J Infect Dis 213:1800–1808. 
c  LpxC-1 has shown to strongly attenuate A. baumannii  virulence in mice (16) 
d  Phase I interrupted due to inflammation at the injection site.  Undesired effects were due to the presence of essential 
pharmacophores (ref.Kalinin_2017) 
e Shown to have problematic in vivo pharmacokinetic properties (ref. Brown 2012) 
f Anethole showed to reduce fluid accumulation of V. cholerae in the in vivo infection model of rabbit ileal loop (ref Zahid_2015) 
g SE-1 has demonstrated to significantly reduce invasion of eukaryotic cells infected with Shigella flexneri (ref_Koppolu_2013) 
h Efficacy has been reported in a murine wound S. aureus model, interestingly not affecting the commensal Staphylococcus 
epidermidis (ref. Sully_2014) 
i S. Typhimurium-infected mice with LED209 24h- post infection (oral administration) substantially  increased  survival rate over 
the non-treated group (80% survival versus 30%, respectively), and similar results were obtained with Francisella tularensis (ref_ 
Rasko 2008). 
j The efficacy of MEDI4893 was compared to active immunization with a nontoxigenic antitoxin in diabetic and non-diabetic mice 
models with S. aureus- infected wounds and showed similar therapeutic effect in wound healing promotion with a greater 
decrease in the bacterial burden in diabetic mice indicating a possible advantage of MEDI4893 (ref_Ortines 2017) 
k In terms of efficacy, results of Phase II study indicated a  significant reduction in the recurrence rates (7% in the treated group 
versus 25% in the placebo group; P<0.001)(ref. Lowy 2010 N Engl J Med 2010;362:197-205) .  Currently undergoing a Phase III 
clinical trial in children with C. difficile infections 
l Although efficacy outcomes are not concluding due to the small sample size, a study in a mice model of severe pneumonia (S. 
pneumoniae infection) and bacteraemia (S. aureus and S. pneumoniae) showed that a combined therapy of CAL02 with 















Table 4. Description of phage therapies currently available and under development and enzybiotics.
Research strategy Name Agent Bacterial target Infectious disease targeted Current stage References
Intesti bacteriophage Phage cocktail
Salmonella, Shigella, E. coli, Proteus, 





Pyo bacteriophage Phage cocktail
Staphylococcus, Streptococcus, 
Pseudomonas, E. coli, and Proteus




Cocktail of 12 natural lytic anti-
P. aeruginosa  bacteriophages
Pseudomonas aeruginosa Burn wound infected with P. aeruginosa Phase 1 / 2 n Jault_2019
Enzybiotics Cpl-711 
Endolysin (degradation of 
peptidoglycan)
MDR Streptococcus pneumoniae S. pneumoniae infections Preclinical 11 o Diez-Martinez_2014
n Results from a Phase 1/2 trial involving 27 patients with burn wound infected with P. aeruginosa indicated that although a decrease in bacterial burden was observed using phage therapy the standard of care still showed better results indicating that higher doses of phages should be used in future studies (ref_Jault2019)
o Cpl-711 showed greater protection than Cpl-711 in animals having received endolysin intraperitoneally 1h post infection ( S. pneumoniae  injected intraperitoneally) (ref actual 38: Diez-Martinez). 
Phage therapy
Table 3. Description of antibacterial agents in the research pipeline following alternative strategies. 
Category Agent Action Bacterial target Infectious disease targeted Current stage References
OP-145 (AMP60.4Ac or P60.4Ac; based on LL-37)
Hypothesized to inhibit 
bacterial adherence
Gram positive Chronic middle ear infection Phase II
Malanovic et al, 2015; 
Molchanova et al 2017; 
de Breij et al 2015; Riool 
et al 2017
Surotomycin Membrane depolarization Clostridiodes difficile Infectious diarrhoea associated with C. difficileDiscontinued Phase III a
knight-connonni et al 
2016; Boix et al, 2017; 
Daley et al, 2017
NVB-302 (lantibiotic; 
polycyclic peptide 
containing thioether amino 
acids)
Inhibition of cell wall 
biosynthesis by lipid II binding 
Clostridiodes difficile and wide rage of 
Gram positive bacteria
C.difficile infection Completed Phase I
Crowther et al, 2013; 
Sandiford, 2019; 
Petrosillo et al 2018
Murepavidin (POL7080; cyclic protegrin analog)Outer membr e biogenesis P. aeruginosa Ventilator associated bacterial pneumonia (Pseudomonal infections)Di continued Phas  III b
Sierra et al, 2017 










Charge driven cell membrane 
desestabilization
A. baumannii, P. aeruginosa, K. 
pneumoniae and anaerobic bacteria 
including Bacteroides spp. and C. difficile
Infections caused by A. baumannii, P. 
aeruginosa, K. pneumoniae and 
anaerobic bacteria including Bacteroides 
spp. and C. difficile
Discovery
Vila-Farres et al, 2015; 
Hashemi et al, 2017; 
Durnás et al, 2017
CSA-13
Antibiofilm activity; bacterial 
membrane Mixed P. aeruginosa and S. aureus biofilm and streptococci biofilmsInfections caused by P. aeruginosa, S. aureus and  Streptococci biofilms 
Discovery Olekson et al, 2017
CPP-PMO conjugate
Gene expression inhibition of 
gyrA
E. faecalis and Staphylococcus aureus (gyrA)E. faecalis and S. aureus infections Discovery Wesolowski et al 2013
CPP-PNA conjugate
Gene expression inhibition of 
rpoA
Lysteria monocytogenes (rpoA) L. monocytogenes infection Preclinical Abushahba et al 2016
PNA
Gene expression inhibition of 
polA
Brucella suis (polA ) B. suis infection Discovery Rajasekaran et al 2013
PNA conjugate
Gene expression inhibition of 
ftsZ
Staphylococcus aureus (ftsZ) S. aureus inifection Discovery Liang et al 2015
a Surotomycin did not show superiority for clinical response or sustained clinical response versus vancomycin and failed to achieve non-inferiority for clinical cure at end of treatment REFERENCE Boix et al 2017  demonstrated non-inferiority versus vancomycin in another trial, but yet failed to demonstrate superiority versus vancomycin REFERENCE Daley et al 2017
n two Phase III studies were suspended due to renal toxicity https://clinicaltrials.gov/ct2/show/NCT03582007?term=murepavadin&rank=1 https://clinicaltrials.gov/ct2/show/NCT03409679?term=murepavadin&rank=2
Antimicrobial 
peptides and 
peptidomimetics
Antisense 
oligonucleotides 
(Gene expression 
inhibitors)
 
